AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 151 min read$XRAY

Gladden Brian T purchased $100K of XRAY

Gladden Brian T purchased 9,985 shares of DENTSPLY SIRONA Inc. (XRAY) at $10.02 ($0.10M total) on 2026-06-15.

Original reporting
SEC EDGAR · Gladden Brian T
Published Jun 15, 2026, 9:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$XRAY
Bullish
low confidence
Mentioned
$XRAY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XRAYBullishLow
01

Why it matters

A director’s open-market purchase provides incremental sentiment information but does not change the company’s fundamentals in the text provided.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still treat it as lower-signal without corroborating fundamental news.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-15 (SEC Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Dentsply Sirona (XRAY).

Company-level read

Ticker impact

$XRAYBullishLow confidence
Context

Dentsply Sirona director Brian T Gladden filed an open-market purchase of 9,985 shares at $10.0150 on 2026-06-15.

Expected impact

Likely limited near-term impact; any effect is typically small and fades unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing is a routine insider transaction (director open-market purchase) with no accompanying guidance, deal, or operational update.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider open-market buys are often discretionary and may reflect diversification, liquidity planning, or routine compensation-related behavior rather than a new bullish thesis.

Key entities

  • issuer
    Dentsply Sirona Inc.

    Subject of the SEC Form 4 insider transaction disclosure (XRAY).

  • insider
    Gladden Brian T

    Director who purchased 9,985 shares on 2026-06-15.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

XRAY insider trading history →

Related articles

SEP 3
$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

insidermonkey.com3 min
AUG 26
$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

dentistrytoday.com2 min
AUG 14
$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

fool.com6 min
AUG 9
$XRAYMed

DENTSPLY SIRONA Q2 Earnings Call Highlights

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

yahoo.com6 min
AUG 7
$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

financialcontent.com3 min
AUG 7
$XRAYMedAI 8/10

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.

tradingview.com6 min